Tumor News and Research

RSS

Researchers identify complex mechanisms involved in metastasis of deadly TNBC

A team of researchers from the Cleveland Clinic and Case Western Reserve School of Medicine have identified critical complex mechanisms involved in the metastasis of deadly "triple negative" breast cancers (TNBC).

17 Jan 2014

Cedars-Sinai researcher to receive 2014 Troland Research Award

Ueli Rutishauser, PhD, assistant professor of neurosurgery and director of human neurophysiology research in the Department of Neurosurgery and the Department of Neurology at Cedars-Sinai, will receive a 2014 Troland Research Award at the National Academy of Sciences annual meeting April 27.

16 Jan 2014

Biothera enhances innate immune responses to Imprime PGG drug candidate

Biothera has enhanced innate immune responses to its cancer immunotherapy drug candidate Imprime PGG in subjects regardless of biomarker status, demonstrating the opportunity to treat a larger patient population. The in vitro research will be presented today at the Cambridge Healthtech Institute's Antibody-Drug Conjugates/Engineering Targeted Therapeutics conference in Palm Springs, CA.

16 Jan 2014

Prostate cancer vaccines receive a boost in funding

The development of two innovative new vaccines that are hoped to offer an alternative to castration therapy for men with recurring prostate cancer, is due for an $8 million boost in funding.

16 Jan 2014

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

A multinational set of seven teams is banding together to develop a drug that may potentially fight many different cancers through an antibody that would work within the body's metabolic system.

16 Jan 2014

Varian Medical Systems' updated ProBeam proton therapy system gets FDA clearance

Varian Medical Systems has received FDA 510(k) clearance for its updated ProBeam proton therapy system.

15 Jan 2014

New stem cell study explains how breast cancer spreads

Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.

15 Jan 2014

BMH-21 chemical compound has ability to shut down a common cancer process

Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.

15 Jan 2014

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

Christopher Parsons, MD, Director of the HIV Malignancies Program at LSU Health Sciences Center New Orleans, is the senior author of a paper that is the first to report that specialized fat (lipid) molecules, called sphingolipids, play a key role in the survival of aggressive lymphomas caused by viruses.

15 Jan 2014

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

A team led by investigators from Massachusetts General Hospital, Brigham and Women's Hospital and the Broad Institute has found that a gene mutation associated with several types of cancer also may be responsible for a rare but debilitating brain tumor called papillary craniopharyngioma.

13 Jan 2014

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Foundation Medicine, Inc. today announced the discovery of a high incidence of ERBB2 (HER2) extracellular domain alterations in patients with micropapillary urothelial carcinoma, a particularly aggressive form of urinary bladder cancer, using FoundationOne. The research was published in the current edition of Clinical Cancer Research.

10 Jan 2014

Life Technologies, Quest Diagnostics sign multi-year license and supply agreement

Life Technologies has completed a multi-year license and supply agreement with Quest Diagnostics, the world's leading provider of diagnostic information services, that gives Quest rights to develop molecular tests on the Ion Torrent next-generation sequencing platform. Under the agreement, Quest may use the platform and related consumables to independently develop new tests for numerous areas of their business.

From Quest Diagnostics 10 Jan 2014

Minority patients and those of lower socioeconomic status are more likely to have advanced thyroid cancer

UCLA researchers have found that minority patients and those of lower socioeconomic status are far more likely to have advanced thyroid cancer when they are diagnosed with the disease than white patients and those in higher economic brackets.

10 Jan 2014

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

Synta Pharmaceuticals Corp. today announced the initiation of three multicenter, randomized trials supported by the Leukemia & Lymphoma Research Fund and Cancer Research UK, evaluating ganetespib in combination with chemotherapy in first-line treatment of patients with AML and high risk MDS.

10 Jan 2014

New study gives hope for novel glioblastoma multiforme treatment

A new study is giving researchers hope that novel targeted therapies can be developed for glioblastoma multiforme, the most common and most aggressive form of brain cancer, after demonstrating for the first time that a gene known as melanoma differentiation associated gene-9/syntenin (mda-9/syntenin) is a driving force behind the disease's aggressive and invasive nature.

9 Jan 2014

Antipsychotic medication can actively combat cells of difficult-to-treat form of ALL

In a prime example of finding new uses for older drugs, studies in zebrafish show that a 50-year-old antipsychotic medication called perphenazine can actively combat the cells of a difficult-to-treat form of acute lymphoblastic leukemia. The drug works by turning on a cancer-suppressing enzyme called PP2A and causing malignant tumor cells to self-destruct.

9 Jan 2014

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

Zymeworks Inc. today announced that it has entered into a licensing and collaboration agreement with ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to develop an undisclosed number of novel bi-specific antibody oncology therapeutics using Zymeworks' proprietary Azymetric platform. Bi-specific antibodies have the potential to provide improved outcomes for patients by simultaneously targeting two tumor associated antigens to induce a synergistic therapeutic response.

9 Jan 2014

Research findings suggest possible blood test to identify cancer-related DNA defects

Some surprising research findings from scientists at The University of Texas MD Anderson Cancer Center suggest it's possible a simple blood test could be developed to determine whether gene mutations associated with pancreatic cancer exist without the need of locating and testing tumor tissue. This appears possible following the discovery that tiny particles the size of viruses called 'exosomes,' which are shed by cancer cells into the blood, contain the entire genetic blueprint of cancer cells. By decoding this genomic data and looking for deletions and mutations associated with cancer, the research team believes this discovery could be translated into a test that helps physicians detect cancer and treat patients.

9 Jan 2014

Weill Cornell Medical College received a $75M grant to expand, enhance cancer research, care programs

Weill Cornell Medical College announced today that it has received a $75 million gift from Sandra and Edward Meyer and the Sandra and Edward Meyer Foundation to expand and enhance the medical college's distinguished cancer research and care programs.

9 Jan 2014

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Rexahn Pharmaceuticals, Inc. a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with solid tumors.

9 Jan 2014

Tumor News and Research

Researchers identify complex mechanisms involved in metastasis of deadly TNBC

Cedars-Sinai researcher to receive 2014 Troland Research Award

Biothera enhances innate immune responses to Imprime PGG drug candidate

Prostate cancer vaccines receive a boost in funding

EU-sponsored TumAdoR project targets relationship between immune system and cancer growth

Varian Medical Systems' updated ProBeam proton therapy system gets FDA clearance

New stem cell study explains how breast cancer spreads

BMH-21 chemical compound has ability to shut down a common cancer process

Research reveals new therapy for preventing production of sphingolipids by lymphoma cells

BRAF mutation associated with other cancers appears to drive papillary craniopharyngiomas

Foundation Medicine announces discovery of high incidence of ERBB2 alterations in MPUC patients

Life Technologies, Quest Diagnostics sign multi-year license and supply agreement

Minority patients and those of lower socioeconomic status are more likely to have advanced thyroid cancer

Synta initiates three multicenter trials to evaluate ganetespib with chemotherapy for AML and MDS

New study gives hope for novel glioblastoma multiforme treatment

Antipsychotic medication can actively combat cells of difficult-to-treat form of ALL

Zymeworks, ImClone Systems partner to develop novel bi-specific antibody oncology therapeutics

Research findings suggest possible blood test to identify cancer-related DNA defects

Weill Cornell Medical College received a $75M grant to expand, enhance cancer research, care programs

Rexahn Pharmaceuticals initiates RX-3117 Phase Ib trial in cancer patients with solid tumors

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News